Valneva provides update following european medicines agency announcement on use of ixchiq® in elderly

Saint herblain (france), may, 07 2025 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced that the european medicines agency (ema) has started a review of valneva's single-dose live attenuated chikungunya vaccine ixchiq® based on reports of serious adverse events (saes) in elderly people. as a temporary measure, while this review is ongoing, ema has suspended the use of the vaccine for individuals over 65 years old. ema has maintained current recommendations for ixchiq® for people from 12 to 64 years of age.
VALN Ratings Summary
VALN Quant Ranking